When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Single-domain antibody - Wikipedia

    en.wikipedia.org/wiki/Single-domain_antibody

    A single-domain antibody is a peptide chain of about 110 amino acids long, comprising one variable domain (V H) of a heavy-chain antibody, or of a common IgG.These peptides have similar affinity to antigens as whole antibodies, but are more heat-resistant and stable towards detergents and high concentrations of urea.

  3. Bi-specific T-cell engager - Wikipedia

    en.wikipedia.org/wiki/Bi-specific_T-cell_engager

    Blinatumomab links T cells with CD19 receptors found on the surface of B cells. The Food and Drug Administration (US) and the European Medicines Agency approved this therapy for adults with Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.

  4. Ozoralizumab - Wikipedia

    en.wikipedia.org/wiki/Ozoralizumab

    Ozoralizumab (trade name Nanozora) is a trivalent anti-tumour necrosis factor alpha (TNFα) nanobody designed for the treatment of inflammatory diseases. [1] Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm.

  5. Bispecific monoclonal antibody - Wikipedia

    en.wikipedia.org/wiki/Bispecific_monoclonal_antibody

    Additional bispecific antibody drugs have since been approved by the US FDA: emicizumab, amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab, epcoritamab, glofitamab. [31] Among the bsAb programs currently under development, the combination of CD3 and tumor surface targets are the most popular targets pairs.

  6. List of drugs granted breakthrough therapy designation

    en.wikipedia.org/wiki/List_of_drugs_granted...

    Treatment of adults with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [2] Repotrectinib

  7. List of gene therapies - Wikipedia

    en.wikipedia.org/wiki/List_of_gene_therapies

    Exagamglogene autotemcel (Casgevy): treatment for sickle cell disease. [11] Gendicine: treatment for head and neck squamous cell carcinoma; Idecabtagene vicleucel (Abecma): treatment for multiple myeloma [12] Lovotibeglogene autotemcel (Lyfgenia): treatment for sickle cell disease. [11] Nadofaragene firadenovec (Adstiladrin): treatment for ...

  8. Many cancer drugs remain unproven 5 years after accelerated ...

    www.aol.com/news/many-cancer-drugs-remain...

    The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. In a new study, researchers found that most cancer drugs granted ...

  9. Monoclonal antibody therapy - Wikipedia

    en.wikipedia.org/wiki/Monoclonal_antibody_therapy

    The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986. This drug found use in solid organ transplant recipients who became steroid resistant. [39] Hundreds of therapies are undergoing clinical trials. Most are concerned with immunological and ...